title: Early participant attrition from clinical trials: role of trial design and logistics.
abstract: BACKGROUND
  Participant attrition from randomized controlled trials reduces the statistical power of the study and can potentially introduce bias. Early identification of potential causes of attrition can help reduce patient attrition. We performed secondary analyses of two trials involving cancer patients.
  
  
  OBJECTIVE
  To identify predictors of attrition during two early phases, i.e., from consent to screening (Phase-1), and from screening to intake interview (Phase-2) in two clinical trials.
  
  
  METHODS
  Cancer patients undergoing chemotherapy were asked to enroll in one of two clinical trials. In each trial the benefits of a cognitive behavioral intervention were compared with a psycho-educational intervention to assist patients to manage cancer and treatment-related symptoms. Following consent patients were screened for their symptoms' severity to determine their eligibility.
  
  
  RESULTS
  Of the 885 consenters 785 completed screening and of the 782 eligible for participation, 713 completed intake interview. In the first phase, longer delays between consent and first contact attempt, lower levels of patient education, minority race, and prolonged duration of screening increased the likelihood of dropping out with a significantly stronger effect on minorities than white patients. In the second phase, low education, being a minority, longer screening delays, and impact of symptom severity on enjoyment of life significantly increased probability of attrition.
  
  
  CONCLUSIONS
  Participant reported causes of attrition were not modeled; however, exclusion of patients who died during the time period of this research meant that most patients leaving the study made a conscious decision to do so.
  
  
  CONCLUSIONS
  To assure preservation of external validity, the time between consent and randomization into the arms of a trial must be held to a minimum. Delays between contacts and run in time, that may include screening patients to assure they will benefit from a trial, must be balanced against rates of attrition. Compressing intervals between contacts is particularly important to retain minorities.
authors.affiliation: Michigan State University, East Lansing, MI 48824, USA. siddiqi@msu.edu
authors.forename: Azfar-E-Alam
authors.initials: AE
authors.lastname: Siddiqi
authors.forename: Alla
authors.initials: A
authors.lastname: Sikorskii
authors.forename: Charles W
authors.initials: CW
authors.lastname: Given
authors.forename: Barbara
authors.initials: B
authors.lastname: Given
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001521:Behavior Therapy; D006801:Humans; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000628:therapy; D010352:Patient Dropouts / Q000706:statistics & numerical data*; D010353:Patient Education as Topic; D016032:Randomized Controlled Trials as Topic / Q000379:methods* / Q000706:statistics & numerical data; D015203:Reproducibility of Results; D012107:Research Design; D012959:Socioeconomic Factors; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents